Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more
Capricor Therapeutics Inc (CAPR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.235x
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has a cash flow conversion efficiency ratio of -0.235x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.69 Million) by net assets ($83.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Capricor Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Capricor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Capricor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Capricor Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Shenzhen Batian Ecotypic Engineering Co Ltd
SHE:002170
|
0.028x |
|
Brederode SA
BR:BREB
|
0.009x |
|
C*Core Technology Co Ltd
SHG:688262
|
0.047x |
|
HAOTF
PINK:HAOTF
|
0.036x |
|
JiLin Sino-Microelectronics Co Ltd
SHG:600360
|
0.476x |
|
Natural Resource Partners LP
NYSE:NRP
|
0.071x |
|
Kunshan Kinglai Hygienic Materials Co Ltd
SHE:300260
|
0.016x |
Annual Cash Flow Conversion Efficiency for Capricor Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $145.46 Million | $-40.00 Million | -0.275x | +75.72% |
| 2023-12-31 | $22.60 Million | $-25.60 Million | -1.133x | -371.49% |
| 2022-12-31 | $11.79 Million | $4.92 Million | 0.417x | +177.85% |
| 2021-12-31 | $31.37 Million | $-16.81 Million | -0.536x | -50.29% |
| 2020-12-31 | $28.20 Million | $-10.05 Million | -0.357x | +64.25% |
| 2019-12-31 | $6.84 Million | $-6.82 Million | -0.997x | +66.79% |
| 2018-12-31 | $4.62 Million | $-13.86 Million | -3.003x | -136.94% |
| 2017-12-31 | $11.23 Million | $-14.23 Million | -1.268x | -132.11% |
| 2016-12-31 | $-4.00 Million | $-15.80 Million | 3.947x | -62.35% |
| 2015-12-31 | $-1.03 Million | $-10.82 Million | 10.484x | +6934.47% |
| 2014-12-31 | $-6.25 Million | $958.56K | -0.153x | -101.34% |
| 2013-12-31 | $-534.88K | $-6.14 Million | 11.487x | +2671.04% |
| 2012-12-31 | $4.89 Million | $-2.19 Million | -0.447x | +92.02% |
| 2011-12-31 | $830.72K | $-4.65 Million | -5.597x | -236.57% |
| 2010-12-31 | $2.60 Million | $-4.32 Million | -1.663x | +14.43% |
| 2009-12-31 | $2.98 Million | $-5.80 Million | -1.943x | +6.78% |
| 2008-12-31 | $5.10 Million | $-10.64 Million | -2.085x | -489.82% |
| 2007-12-31 | $15.20 Million | $-5.37 Million | -0.353x | -183.02% |
| 2006-12-31 | $-130.58K | $-55.60K | 0.426x | +85.78% |
| 2005-12-31 | $-77.62K | $-17.79K | 0.229x | -13.00% |
| 2004-12-31 | $-58.76K | $-15.48K | 0.263x | -48.52% |
| 2003-12-31 | $-40.69K | $-20.82K | 0.512x | -12.35% |
| 2002-12-31 | $-24.53K | $-14.32K | 0.584x | -59.91% |
| 2001-12-31 | $-8.94K | $-13.02K | 1.456x | +152.13% |
| 2000-12-31 | $13.36K | $-37.32K | -2.793x | -291.50% |
| 1999-12-31 | $-617.00 | $-900.00 | 1.459x | -- |